Let's Restore Some Of The Funding To NIH
Published Oct. 7, 2013 • Read time: 4m
The political warfare over the government shutdown continues, but the battlegrounds are constantly shifting. Late last week, following widespread reports of children with cancer unable to enter NIH-sponsored clinical trials with almost three-quarters of the institution’s staff furloughed, Republicans tried to restore NIH funding. Democrats were having none of it, however, accusing Republicans of pitting one deserving group against another.
If there were agreement on restoring at least some funding to NIH, a good compromise might be to provide it only to certain components of the multi-center institution. In fact, all research carried out within or supported by NIH is not equal, and the projects carried out by its National Center for Complementary and Alternative Medicine (NCCAM) – which was in the first place the brainchild not of scientists but of politicians — are clearly a weak link.
NCCAM’s mission is “to define, through rigorous scientific investigation, the usefulness and safety of complementary and alternative medicine interventions and their roles in improving health and health care.” But peer-review there is deficient – in effect, the inmates run the asylum – and many of its projects are trivial and almost all of the interventions tested have proven to be worthless. For example, a recent study funded by the center found that cranberry juice cocktail was no better than placebo at preventing recurring urinary tract infections. Other studies funded by the Center include, “Metabolic and Immunologic Effects of Meditation,” “Long-Term Chamomile Therapy of Generalized Anxiety Disorder,” and “Restorative Yoga for Therapy of the Metabolic Syndrome.” Sounds an awful lot like the late-night TV ads for snake oil of all sorts.
President Calls Drug Addiction a Health Problem
Lawmakers Hail New Opioid Rules -- But Call for More
No Opiates for the Masses?
Obamacare's Tax-Time Torment
Perhaps worst of all is the $31.6 million, 10-year multicenter study, the Trial to Assess Chelation Therapy (TACT), conducted under the aegis of NCCAM and the National Heart, Lung and Blood Institute, to investigate the effects of disodium EDTA (a chemical that chelates, or binds, atoms so that they can be removed from a system) on coronary artery disease. It was known from the start that the probability of the study yielding usable – let alone clinically important — results approached zero. Perhaps because the trial was “requested” by two powerful members of Congress, NIH pursued it in spite of the fact that chelation therapy had been discredited by four controlled trials performed during the 1990s. Even the NIH conceded that “there is a lack of adequate prior research to verify EDTA chelation therapy’s safety and effectiveness for coronary artery disease. The bulk of the evidence supporting the use of EDTA chelation therapy is in the form of case reports and case series.” The results of the study were finally published earlier this year. Dr. Steven Nissen of the Department of Cardiovascular Medicine at the Cleveland Clinic Foundation condemned it as “a situation in which many important limitations in the design and execution of a clinical trial compromise the reliability of the study and render the results difficult to interpret. Unfortunately, the efforts of these investigators fell short of the minimum level of quality necessary to adequately answer the question they sought to investigate.” In other words, garbage in-garbage out, and $31.6 million of federal funds squandered. Predictably squandered.
The sort of “research” funded by NCCAM, to the tune of $130 million annually, is an affront to the NIH and NIH-funded investigators who are at the cutting edge of their disciplines and who are facing increasing difficulty getting federal funding even for studies that are highly ranked on the basis of scientific merit. In 2011, the percentage of research grant proposals that were funded by NIH fell to 18 percent, a record low. The squandering of research funds particularly shortchanges inexperienced scientists who do not have an extensive record of achievement. Bruce Alberts, the editor of the journal Science and the former president of the National Academy of Sciences, wrote in a November 2011 editorial (well before the federal budget sequester and last week’s shutdown), “There is an ominous sense of a major crisis brewing. Budget realities have begun to constrain scientific progress across the board, with an especially heavy impact on the careers of young scientists.”
Let’s not let a crisis go to waste. Let’s begin to think about which entities and projects in the massive federal budget actually deserve to be funded.
This article is reprinted from Forbes with permission from the Hoover Institution at Stanford University.

Democrats Won the Midterms. Common Sense Won, Too
Jordanne Kemper • RealClearPolitics
The 120th Congress Shapes Up
Carolina Lumetta • RealClearPolitics
Flooding GOP Primaries With Democrats
Robert Natelson • RealClearPolitics
Washington Keeps Rewarding Oracle—Veterans Keep Paying the Price
Darin Gaub • RealClearPolitics
The Seeds of Unrestricted Warfare
John Teichert • RealClearPolitics
The Primary System Is Losing the Next Generation
Sean Trende • RealClearPolitics
RCP Today
Top stories on RealClearPolitics
The Takeaway
Polling intelligence and analysis delivered to your inbox
World News
Featuring the latest world news
Policy
Featuring the latest policy news
Support Our Mission
As part of RealClearPolitics, authors aim to provide balanced, non-partisan analysis by presenting top reporting and commentary from all sides of the political spectrum.
Trusted by policymakers and citizens alike since 2000
